Treatment of psoriasis with crisaborole.

Abstract

Crisaborole, a topical phosphodiesterase-4 (PDE4) inhibitor, is effective in patients with atopic dermatitis. As systemic PDE4 inhibition has also been used with success in psoriasis, clinical trials are underway to determine the utility of topical PDE4 inhibitors in these patients. However, there is no current literature documenting use of crisaborole for psoriasis. Here, we present two cases in which patients with psoriasis were treated successfully with crisaborole.

• Authors: Erica B Lee, Mark G Lebwohl, Jashin J Wu
• Journal: The Journal of dermatological treatment (J Dermatolog Treat) Vol. 30 Issue 2 Pg. 156-157 (Mar 2019) ISSN: 1471-1753 [Electronic] England
• PMID: 29812961 (Publication Type: Case Reports, Journal Article)

Chemical References

• Boron Compounds
• Bridged Bicyclo Compounds, Heterocyclic
• Phosphodiesterase 4 Inhibitors
• crisaborole

Topics

• Aged
• Boron Compounds (therapeutic use)
• Bridged Bicyclo Compounds, Heterocyclic (therapeutic use)
• Female
• Humans
• Middle Aged
• Phosphodiesterase 4 Inhibitors (therapeutic use)
• Psoriasis (drug therapy)